Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Liying Liu
Observed name:
L. Liu
Institutions:
Zhejiang Chinese Medical University,
Liaoning University
Observed institutions:
Zhejiang Chinese Medical University,
Liaoning University,
Tianjin Medical University Cancer Institute and Hospital,
Zhujiang Hospital,
Tianjin Medical University,
Southern Medical University,
Xi'an Jiaotong University
show all 7
ORCID:
0009-0002-4760-9668
Observed ORCIDs:
0009-0002-4760-9668,
0000-0002-4989-694X
OpenAlex ID:
A5073271467
HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers
2023
·
Liying Liu
, Yanan Xie
, et al.
·
iMeta
·
78
PDF
LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial
2021
·
X. Shang
, C. Zhang
, et al.
·
Annals of Oncology
·
16
FUT3 promotes gastric cancer cell migration by synthesizing Lea on ITGA6 and GLG1, affecting adhesion and vesicle distribution
2024
·
Fei Wu
, Li Cao
, et al.
·
Life Sciences
·
9
MECP2 promotes migration and invasion of gastric cancer cells via modulating the Notch1/c-Myc/mTOR signaling pathways by suppressing FBXW7 transcription
2020
·
Lingyu Zhao
, Xiaofei Wang
, et al.
·
Research Square
·
8
PDF
Xanthoangelol alleviates ischemic stroke injury by inhibiting the inflammatory activation of microglia
2024
·
Wenqi Wang
, Biying Ma
, et al.
·
Clinical Traditional Medicine and Pharmacology
·
7
1558P Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
2023
·
H. Jiang
, X. Shang
, et al.
·
Annals of Oncology
·
6
PDF
4-Hydroxyderricin attenuates ischemic brain injury and neuroinflammation by upregulating haptoglobin expression in microglia
2025
·
Biying Ma
, Wenqi Wang
, et al.
·
Phytomedicine
·
2
376O Randomized, multicenter trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small cell lung cancer: NCT01631357
2020
·
L. Liu
, Q. Gao
, et al.
·
Annals of Oncology
·
1
PDF
386P A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
2020
·
L. Zhou
, X. Zhang
, et al.
·
Annals of Oncology
·
1
PDF
Pseudolaric Acid A and Pseudolaric Acid B Exert Dual Neuroprotection: Inhibiting Aβ-Induced PC12 Apoptosis and Neuroinflammation with Therapeutic Potential in Alzheimer’s Disease Mice
2026
·
Dan Wang
, Liying Liu
, et al.
·
ACS Pharmacology & Translational Science
Angelica keiskei extract inhibits LPS-induced activation of microglia and ameliorates acute cerebral ischemic injury in mice
2026
·
Jiaqian Yang
, Wenqi Wang
, et al.
·
Journal of Functional Foods
PDF
166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phase III clinical study (Keystone-002)
2021
·
H. Jiang
, X. Shang
, et al.
·
Annals of Oncology
24MO Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small cell lung cancer
2020
·
L. Liu
, Q. Gao
, et al.
·
Annals of Oncology
PDF
Prognostic Significance of Pd‐l1 and Phosphorylated Erk Expression in T‐cell Lymphoma: Pd‐1/pd‐l1 Axis Activates Intracellular Erk Signaling in Tumor Cells
2019
·
X. Wang
, L. Liu
, et al.
·
Hematological Oncology
Show more works
View as search
Works count:
14
Citation count:
128
H-index:
6
I10-index:
2
Year
Topic
Type